Cystic fibrosis
- 1 April 2002
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Infectious Diseases
- Vol. 15 (2), 175-182
- https://doi.org/10.1097/00001432-200204000-00013
Abstract
Cystic fibrosis is the most common lethal inherited disorder with autosomal recessive inheritance. Major progress has been made in understanding the molecular mechanisms leading to increased susceptibility to Pseudomonas aeruginosa colonization. Persistent respiratory infection with P. aeruginosa leads to progressive pulmonary inflammation and is the major cause of morbidity and mortality. Treatment and prophylaxis of respiratory infection has improved the median survival and quality of life of cystic fibrosis patients. In the future, treatment of the underlying genetic defect may be possible.Keywords
This publication has 39 references indexed in Scilit:
- Anti‐inflammatory effects of macrolides in lung disease*Pediatric Pulmonology, 2001
- Effect of continuous antistaphylococcal therapy on the rate ofP. aeruginosa acquisition in patients with cystic fibrosisPediatric Pulmonology, 2001
- Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensusEuropean Respiratory Journal, 2000
- Cross infection between cystic fibrosis patients colonised with Burkholderia cepaciaThorax, 1998
- Long-term azithromycin may improve lung function in children with cystic fibrosisThe Lancet, 1998
- Cystic Fibrosis Airway Epithelia Fail to Kill Bacteria Because of Abnormal Airway Surface FluidCell, 1996
- Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks.Thorax, 1996
- Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period.Archives of Disease in Childhood, 1994
- Evidence for a Clonal Origin of Methicillin Resistance in Staphylococcus aureusScience, 1993
- The changing epidemiology of cystic fibrosisThe Journal of Pediatrics, 1993